^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Viral entry inhibitor

    Related drugs:
    2ms
    PATRONUS: Pragmatic Amiodarone Trial to Reduce Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery (clinicaltrials.gov)
    P4, N=242, Not yet recruiting, Massachusetts General Hospital | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Jan 2027 --> Jan 2028
    Trial completion date • Trial primary completion date
    2ms
    SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. (clinicaltrials.gov)
    P2, N=95, Active, not recruiting, Vir Biotechnology, Inc. | Trial completion date: Aug 2029 --> May 2032 | Trial primary completion date: Aug 2029 --> Nov 2031
    Trial completion date • Trial primary completion date
    2ms
    BRIGHTE : Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients (clinicaltrials.gov)
    P3, N=371, Active, not recruiting, ViiV Healthcare | Trial completion date: Sep 2026 --> Jan 2027
    Trial completion date
    2ms
    Clinical Study to Evaluate the Efficacy and Safety of HH-006 in Patients With Chronic Hepatitis B Virus Infection (clinicaltrials.gov)
    P2, N=45, Recruiting, Huahui Health | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    VIR-2218-1006: A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFN? in Subjectsnwith Chronic Hepatitis B Virus Infection (2024-513177-48-00)
    P1/2, N=24, Completed, Vir Biotechnology Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    Pegasys (pegylated interferon α -2a)
    3ms
    ARN-75039 Lassa Fever Treatment in West Africa (clinicaltrials.gov)
    P2, N=135, Active, not recruiting, Arisan Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    3ms
    VISTA: HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, TaiMed Biologics Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD4 (CD4 Molecule)
    3ms
    START-POAF: Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Patients Pilot Trial (clinicaltrials.gov)
    P3, N=400, Recruiting, Population Health Research Institute | Trial completion date: Sep 2026 --> Nov 2028 | Trial primary completion date: Jun 2026 --> Aug 2028
    Trial completion date • Trial primary completion date
    3ms
    Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer (clinicaltrials.gov)
    P2, N=90, Recruiting, OHSU Knight Cancer Institute | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2026 --> Aug 2027
    Trial completion date • Trial primary completion date
    3ms
    Lipid‑disrupting effects of an organochlorine mixture in Sertoli TM4 cells reveal testicular obesogen mechanisms. (PubMed, Arch Toxicol)
    These responses differed from those elicited by a fatty acid mixture or the lipotoxicant amiodarone and did not appear to involve androgen receptor, aryl hydrocarbon receptor, or peroxisome proliferator‑activated α signaling, suggesting distinct lipid‑centered mechanisms...Notably, OC‑MIX selectively altered phospholipid and lysophospholipid species in Sertoli TM4 cells, indicating interference with membrane remodeling and lipid‑dependent signaling. Overall, these findings support the hypothesis that persistent organochlorines act as testicular obesogens, contributing to male reproductive dysfunction through selective, lipid‑disrupting mechanisms.
    Journal
    |
    AR (Androgen receptor)
    3ms
    Amiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery (clinicaltrials.gov)
    P3, N=184, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    3ms
    Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study (clinicaltrials.gov)
    P3, N=274, Recruiting, Ansun Biopharma, Inc. | Trial completion date: Aug 2025 --> Sep 2028 | Trial primary completion date: Aug 2025 --> Sep 2028
    Trial completion date • Trial primary completion date